Sinovac Biotech, Ltd (SVA) Tops Q4 EPS by 2c

Sinovac Biotech, Ltd (NASDAQ: SVA) reported Q4 EPS of $0.05, $0.02 better than the analyst estimate of $0.03. Revenue for the quarter came in at $21.1 million versus the consensus estimate of $19.5 million.

For earnings history and earnings-related data on Sinovac Biotech, Ltd (SVA) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Nebius soars on second quarter revenue beat
• Fervo Energy Company (FRVO) Reports Q2 Loss of $0.38
• Octave Intelligence plc (OCTV) Tops Q2 EPS by 4c ; Offers Guidance